U.K. May Retain Value-Based Pricing, Even If Health Care Bill Fails
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.K.’s Health and Social Care Bill is struggling in parliament, but even if it falls, the government’s plans for value-based drug pricing may survive.